EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieKlinische Studie (Phase III)

Long‐term safety and tolerability of zavegepant 10‐mg nasal spray with concomitant use of anti‐calcitonin gene‐related peptide monoclonal antibodies or other select preventive migraine medications: Results from a phase 2/3 open‐label study

Gary Berman, Kathleen Mullin, Timothy Smith, Linda Mosher, Samantha Sweeney, Robert J Fountaine

Headache: The Journal of Head and Face Pain · 2025

DOI: 10.1111/head.14954 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Headache: The Journal of Head and Face Pain, 2025. Verfasst von Gary Berman und 5 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Research Institute, Inc, Minneapolis, Minnesota, USA. Hauptthemen laut MEDLINE: Migraine Disorders, Calcitonin Gene-Related Peptide Receptor Antagonists, Calcitonin Gene-Related Peptide, Antibodies, Monoclonal. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: Biohaven Pharmaceuticals, Pfizer Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To evaluate the safety and tolerability of zavegepant (ZAV) when used as needed for acute treatment of migraine in patients taking concomitant preventive migraine medications (anti‐calcitonin gene‐related peptide monoclonal antibodies [CGRP mAbs] or other select preventive migraine medications [OSPs]).

Background

People with migraine often use preventive and acute treatments concomitantly for breakthrough attacks. ZAV 10‐mg nasal spray is the first intranasal, small‐molecule CGRP receptor antagonist approved for the acute treatment of migraine with or without aura in adults.

Methods

This was a subgroup analysis of data from a multicenter, single‐arm, open‐label, phase 2/3 clinical trial that assessed the safety and tolerability of ZAV for the acute treatment of migraine. Participants self‐administered 1 ZAV dose/day as needed up to 8 times/month for up to 52 weeks to treat migraine attacks of any severity. Participants were categorized into five cohorts based on their current or concomitant use of preventive treatments: ZAV + CGRP mAbs, ZAV + OSPs, ZAV + CGRP mAbs or OSPs, ZAV monotherapy (ZAVmono), and the overall study population. Adverse events (AEs), clinical laboratory results, and vital signs data were evaluated and summarized descriptively.

Results

A total of 603 participants self‐administered ≥1 dose of ZAV and 341 participants (56.6%) completed the study. Among the 603 ZAV‐treated participants, 39 (6.5%) received ZAV + CGRP mAbs, 72 (11.9%) received ZAV + OSPs, 103 (17.1%) received ZAV + CGRP mAbs or OSPs (eight participants received both CGRP mAbs and OSPs), and 500 (82.9%) received ZAVmono. Baseline characteristics were similar across cohorts. The mean number of ZAV doses self‐administered per month was similar across cohorts (3.1–3.3). The proportion of participants experiencing an AE was similar across cohorts (range: 73.6–76.9%). The most frequent AEs were dysgeusia (range across cohorts: 28.2–41.7%), nasal discomfort (9.7–15.4%), COVID‐19 (7.2–8.7%), nausea (4.2–10.3%), back pain (4.4–15.4%), throat irritation (4.4–12.8%), and nasal congestion (5.2–7.7%). Most AEs had mild‐to‐moderate severity and resolved without treatment. The proportion of participants who discontinued due to an AE was similar across cohorts (range: 4.2–7.7%). No serious AEs related to ZAV treatment occurred. The proportion of participants who experienced a local‐irritation AE was similar across cohorts (range: 49.4–51.4%), as was the proportion who experienced a hepatic‐related AE (3.8–7.7%). No AEs related to medication‐overuse headache, suicidality, or cardiovascular events occurred. No clinically meaningful trends in laboratory test results or vital signs were observed.

Conclusion

Self‐administration of ZAV 10‐mg nasal spray for the acute treatment of migraine up to 8 times/month for up to 52 weeks appeared well‐tolerated irrespective of concomitant use of CGRP mAbs or OSPs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Migraine DisordersCalcitonin Gene-Related Peptide Receptor AntagonistsCalcitonin Gene-Related PeptideAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedHumansMaleAdultFemaleMiddle AgedNasal SpraysDrug Therapy, CombinationYoung Adult

Stichwörter der Autor:innen

calcitonin gene‐related peptide receptor antagonistclinical trialmigrainepreventive migraine treatmentsafetyzavegepant

Substanzen

Calcitonin Gene-Related Peptide Receptor AntagonistsCalcitonin Gene-Related PeptideNasal SpraysAntibodies, MonoclonalAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Clinical Research Institute, Inc, Minneapolis, Minnesota, USA.
  • New England Institute for Neurology and Headache, Stamford, Connecticut, USA.
  • StudyMetrix Research, St Louis, Missouri, USA.
  • Pfizer Inc, Groton, Connecticut, USA.
  • Pfizer Inc, New York, New York, USA.

Förderung

  • Biohaven Pharmaceuticals
  • Pfizer Inc

Zitieren

APA

Berman, G., Mullin, K., Smith, T., Mosher, L., Sweeney, S., & Fountaine, R. J. (2025). Long‐term safety and tolerability of zavegepant 10‐mg nasal spray with concomitant use of anti‐calcitonin gene‐related peptide monoclonal antibodies or other select preventive migraine medications: Results from a phase 2/3 open‐label study. Headache: The Journal of Head and Face Pain. https://doi.org/10.1111/head.14954

Vancouver

Berman G, Mullin K, Smith T, Mosher L, Sweeney S, Fountaine RJ. Long‐term safety and tolerability of zavegepant 10‐mg nasal spray with concomitant use of anti‐calcitonin gene‐related peptide monoclonal antibodies or other select preventive migraine medications: Results from a phase 2/3 open‐label study. Headache: The Journal of Head and Face Pain. 2025. doi:10.1111/head.14954

BibTeX
@article{Berman2025,
  author = {Berman, Gary and Mullin, Kathleen and Smith, Timothy and Mosher, Linda and Sweeney, Samantha and Fountaine, Robert J},
  title = {Long‐term safety and tolerability of zavegepant 10‐mg nasal spray with concomitant use of anti‐calcitonin gene‐related peptide monoclonal antibodies or other select preventive migraine medications: Results from a phase 2/3 open‐label study},
  journal = {Headache: The Journal of Head and Face Pain},
  year = {2025},
  doi = {10.1111/head.14954}
}
Kostenlos starten →